Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2021

01-03-2021 | Pathology | ASO Author Reflections

ASO Author Reflections: Undertreatment of Pancreatic Cancer After Resection: Don’t Get Fooled by Favorable Final Pathology

Authors: Elizabeth Olecki, MD, Niraj Gusani, MD, MS, FACS, Chan Shen, PhD

Published in: Annals of Surgical Oncology | Issue 3/2021

Login to get access

Excerpt

Landmark trials, including CONKO-11 and ESPAC-12, have established that adjuvant chemotherapy in surgically resected pancreatic cancer leads to improved overall survival. Despite evidence from trials and guideline recommendations for both surgical resection and chemotherapy in all early-stage pancreatic cancers, undertreatment, in the form of omission of chemotherapy, has been found to be as high at 60% in those who have undergone resection.3 Demographic and socioeconomic factors have previously been identified to be associated with undertreatment. However, tumor biology, long considered the ‘king’ of all factors affecting outcomes in surgical oncology,4 has not previously been evaluated as a potential factor associated with undertreatment in pancreatic cancer. …
Literature
1.
Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81.CrossRef
2.
Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358(9293):1576–85.CrossRef
3.
Bergquist JR, Ivanics T, Shubert CR, Habermann EB, Smoot RL, Kendrick ML, et al. Type of resection (Whipple vs. Distal) does not affect the national failure to provide post-resection adjuvant chemotherapy in localized pancreatic cancer. Ann Surg Oncol. 2017;24(6):1731–8.CrossRef
4.
Cady B. Basic principles in surgical oncology. Arch Surg. 1997;132(4):338–46.CrossRef
5.
Metadata
Title
ASO Author Reflections: Undertreatment of Pancreatic Cancer After Resection: Don’t Get Fooled by Favorable Final Pathology
Authors
Elizabeth Olecki, MD
Niraj Gusani, MD, MS, FACS
Chan Shen, PhD
Publication date
01-03-2021
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 3/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-09079-0

Other articles of this Issue 3/2021

Annals of Surgical Oncology 3/2021 Go to the issue

Pancreatic Tumors

Reconsidering the Optimal Regional Lymph Node Station According to Tumor Location for Pancreatic Cancer

Hepatobiliary Tumors

Two-Stage Hepatectomy for Bilateral Colorectal Liver Metastases: A Multi-institutional Analysis

ASO Author Reflections

ASO Author Reflections: Extracapsular Spread in Melanoma Lymphadenopathy: Prognostic Implications, Classification, and Management

Gastrointestinal Oncology

Analysis of the Survival Impact of Postoperative Chemotherapy After Preoperative Chemotherapy and Resection for Gastric Cancer

ASO Author Reflections

ASO Author Reflections: Using Tumor Genomics to Predict Axillary Response to Chemotherapy in Breast Cancer

Breast Oncology

Axillary Downstaging in ER+/HER2− Breast Cancer: OncotypeDX As a Tool to Guide Neoadjuvant Approach